Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,41%
1 076,13
-15,38
-1,41%
—1 091,511 090,401 090,401 073,69——
SIXC
Communications
SIXC
Communications
SIXC
-0,55%
606,74
-3,37
-0,55%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,88%
1 248,82
+10,84
+0,88%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,17%
1 724,36
-20,35
-1,17%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,72%
635,59
-4,59
-0,72%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-0,76%
843,15
-6,43
-0,76%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,55%
216,29
-1,19
-0,55%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,08%
3 263,41
+2,72
+0,08%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,34%
939,24
-3,21
-0,34%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,29%
1 462,56
-4,24
-0,29%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,71%
2 380,40
-17,10
-0,71%
—2 397,502 395,032 412,012 370,64——
EVO:NASDAQ
Evotec SE
3,12 $
+0,97%
(+0,030) 1D
4 մյս, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVO...
Open
3,18 $
High
3,22 $
Low
3,10 $
Mkt. cap
1,10 մլրդ
Avg. vol.
109,95 հզր
Volume
75,24 հզր
52-wk high
4,80 $
52-wk low
2,31 $
EPS
-0,34 $
Beta
1,94
Shares outstanding
355,76 մլն
No. of employees
4 հզր
News stories
From sources across the web
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
About Evotec SE
CEO-
Employees4,47 հզր
Founded1993
Headquarters-
Sector-
Websiteevotec.com
Last report
08 ապր, 2026 թ.
Fiscal Period
Q4 2025
Normalized EPS / Estimate
0,04/ -EUR
0,00%miss
Revenue / Estimate
788,37 մլն/ (265,56 մլն est.)EUR
+196,87%beat
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
2025 թ. մրտ
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
Revenue
199,98 մլն
171,24 մլն
163,89 մլն
253,27 մլն
Cost of goods sold
172,75 մլն
162,64 մլն
163,95 մլն
174,81 մլն
Cost of revenue
172,75 մլն
162,64 մլն
163,95 մլն
174,81 մլն
Research and development expenses
10,76 մլն
8,21 մլն
8,71 մլն
9,83 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
47,70 մլն
41,61 մլն
42,31 մլն
44,35 մլն
Operating expense
47,04 մլն
37,19 մլն
43,53 մլն
55,25 մլն
Total operating expenses
219,79 մլն
199,83 մլն
207,48 մլն
230,06 մլն
Operating income
-19,82 մլն
-28,60 մլն
-43,59 մլն
23,21 մլն
Other non operating income
-6,86 մլն
-10,64 մլն
1,19 մլն
-33,96 մլն
EBT including unusual items
-29,85 մլն
-43,42 մլն
-42,96 մլն
29,46 մլն
EBT excluding unusual items
-29,66 մլն
-44,67 մլն
-43,36 մլն
18,35 մլն
Income tax expense
1,73 մլն
59,00 հզր
127,00 հզր
14,84 մլն
Effective tax rate
-5,78%
-0,14%
-0,30%
50,37%
Other operating expenses
-11,41 մլն
-12,63 մլն
-7,50 մլն
1,07 մլն
Net income
-31,58 մլն
-43,48 մլն
-43,09 մլն
14,62 մլն
Net profit margin
-15,79%
-25,39%
-26,29%
5,77%
Earnings per share
-
-
-0,24
-
Interest and investment income
-
1,21 մլն
841,00 հզր
11,84 մլն
Interest expense
-2,41 մլն
-6,00 մլն
-2,28 մլն
-
Net interest expenses
-2,41 մլն
-4,79 մլն
-1,44 մլն
11,84 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
76,50 հզր
-3,42 մլն
-18,27 մլն
41,91 մլն
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer